Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

112.15EUR
9:57am EDT
Change (% chg)

€0.40 (+0.36%)
Prev Close
€111.75
Open
€112.15
Day's High
€112.55
Day's Low
€109.55
Volume
264,663
Avg. Vol
411,370
52-wk High
€112.55
52-wk Low
€70.64

Latest Key Developments (Source: Significant Developments)

Galapagos NV Files For Potential Mixed Shelf Offering Size, Not Disclosed
Friday, 29 Mar 2019 06:34pm EDT 

March 29 (Reuters) - Galapagos NV ::GALAPAGOS NV FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Galapagos Increases Share Capital Through Warrant Exercises
Wednesday, 20 Mar 2019 05:01pm EDT 

Mar 21(Reuters) - GALAPAGOS NV ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES.ISSUES 149,370 NEW ORDINARY SHARES FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF 3,480,747.50 EUROS.  Full Article

Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis
Friday, 4 Jan 2019 04:01pm EST 

7/1/2019(Reuters) - GALAPAGOS ::SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS.IN EXCHANGE FOR GLOBAL COMMERCIALIZATION RIGHTS TO GALAPAGOS, FIBROCOR WILL RECEIVE AN UPFRONT PAYMENT.FIBROCOR WILL POTENTIALLY RECEIVE FURTHER MILESTONE AND ROYALTY PAYMENTS.GALAPAGOS WILL BE RESPONSIBLE FOR ALL FURTHER DEVELOPMENT OF THE PROGRAM.  Full Article

Galapagos Receives Fast Track Designation From FDA For GLPG1972/S201086 In Osteoarthritis
Tuesday, 27 Nov 2018 04:22pm EST 

Nov 27 (Reuters) - Galapagos NV ::GALAPAGOS RECEIVES FAST TRACK DESIGNATION FROM FDA FOR GLPG1972/S201086 IN OSTEOARTHRITIS.  Full Article

Galapagos 9-Month Revenue Rises To 205.1 Million Euros
Wednesday, 24 Oct 2018 04:03pm EDT 

Oct 25 (Reuters) - GALAPAGOS ::REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION.9-MONTH OPERATING LOSS DECREASED BY EUR 9.1 MILLION TO EUR 53.5 MILLION.9-MONTH NET LOSS DECREASED BY EUR 41.7 MILLION TO EUR 44.2 MILLION.CASH AND CASH EQUIVALENTS ON 30 SEPT 2018 OF EUR1,343.7 MILLION.IN Q4, EXPECTS TO PRESENT MORE DETAILED FINDINGS FROM THE EQUATOR, TORTUGA, AND FINCH 2 TRIALS WITH FILGOTINIB.WILL ALSO PRESENT FIRST DATA AND DEVELOPMENT STRATEGY WITH REGARD TO TOLEDO, OUR NEW PROGRAM IN INFLAMMATORY INDICATIONS.EXPECT TO START DOSING IN THE ISABELA (PH3 IPF `1690) AND PINTA (PH2 IPF `1205) PATIENT TRIALS.DUE TO REVISION OF THE ABBVIE COLLABORATION AGREEMENT IN CF, CO IS REDUCING EXPECTED OPERATIONAL CASH BURN FROM THE LAST GUIDED EUR180-200 MILLION TO EUR140-160 MILLION IN 2018.  Full Article

Galapagos Announces Positive Trial Results With Filgotinib In Psoriatic Arthritis And Ankylosing Spondylitis
Monday, 22 Oct 2018 01:15pm EDT 

Oct 22 (Reuters) - GALAPAGOS NV ::REG-POSITIVE TRIAL RESULTS WITH FILGOTINIB IN PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS BOTH PUBLISHED IN THE LANCET.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH PSORIATIC ARTHRITIS.RESULTS OF EQUATOR AND TORTUGA STUDIES DEMONSTRATE THAT FILGOTINIB IMPROVED SIGNS AND SYMPTOMS OF PATIENTS WITH ANKYLOSING SPONDYLITIS.  Full Article

Galapagos: Capital Increase Of EUR 2.0 Million
Wednesday, 3 Oct 2018 04:02pm EDT 

Oct 4(Reuters) - GALAPAGOS ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES.ISSUED 135,485 NEW ORDINARY SHARES ON 3 OCTOBER 2018, FOR A TOTAL CAPITAL INCREASE (INCLUDING ISSUANCE PREMIUM) OF EUR 2,013,590.25.  Full Article

Gilead & Galapagos Announce Filgotinib Meets Primary Endpoint In First Phase 3 Study In Rheumatoid Arthritis
Tuesday, 11 Sep 2018 04:05pm EDT 

Sept 11 (Reuters) - Galapagos NV ::GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS.GALAPAGOS NV - BOTH FILGOTINIB DOSES ALSO ACHIEVED ALL KEY SECONDARY EFFICACY ENDPOINTS.GALAPAGOS NV - TOLERABILITY OF FILGOTINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES.GALAPAGOS - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN FINCH 2 TRIAL, WITH NO NEW SAFETY SIGNALS VERSUS THOSE REPORTED IN PREVIOUS TRIALS OF FILGOTINIB.  Full Article

Galapagos NV reports H1 Group Revenues Of €101.9 Million
Thursday, 2 Aug 2018 04:02pm EDT 

Aug 2 (Reuters) - Galapagos Nv ::H1 GROUP REVENUES OF €101.9 MILLION.H1 OPERATING LOSS OF €65.8 MILLION.H1 NET LOSS OF €59.1 MILLION.CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION.DUE TO COLLABORATION WITH NOVARTIS, CO CUTS EXPECTATIONS FOR OPERATIONAL CASH BURN FROM ORIGINALLY GUIDED €220-240 MILLION TO €180-200 MILLION IN 2018.  Full Article

Morphosys And Galapagos Sign Global License Agreement For Mor106 With Pharma Partner
Thursday, 19 Jul 2018 01:15am EDT 

July 19 (Reuters) - GALAPAGOS NV ::REG-MORPHOSYS AND GALAPAGOS SIGN GLOBAL LICENSE AGREEMENT FOR MOR106 WITH TOP PHARMA PARTNER.EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH NOVARTIS ON MOR106.UP-FRONT PAYMENT OF EUR 95 MILLION (USD 111 MILLION*) AND POTENTIAL MILESTONE PAYMENTS OF UP TO APPROXIMATELY EUR 850 MILLION (USD 1 BILLION*).NOVARTIS TO BEAR ALL FUTURE RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS.AGREEMENT BETWEEN MORPHOSYS, GALAPAGOS, AND NOVARTIS IS SUBJECT TO CLEARANCE BY US ANTITRUST AUTHORITIES UNDER HART-SCOTT-RODINO ACT.ROYALTIES UP TO LOW-TEENS TO LOW-TWENTIES.  Full Article

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS